Trial Profile
A Randomized, Double-blind, Multi-center Phase III Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma Who Have Progressed After Therapy With a Fluoropyrimidine-containing Regimen.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms GRANITE-2; RADPAC
- 27 Jan 2020 Status changed from active, no longer recruiting to completed.
- 16 Aug 2019 Planned End Date changed from 1 Apr 2019 to 1 Aug 2019.
- 07 Mar 2019 Planned End Date changed from 1 Aug 2018 to 1 Apr 2019.